Teva Pharmaceutical Industries LimitedTEVANYSE
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, above historical average, strong compound growth.
Left:
||||
Year-over-year research & development expense growth
Latest
10.70%
↑ 530% above average
Average (9y)
1.70%
Historical baseline
Range
High:77.62%
Low:-39.02%
CAGR
+17.6%
Consistent expansion
| Period | Value |
|---|---|
| 2024 | 10.70% |
| 2023 | 13.72% |
| 2022 | -23.40% |
| 2021 | -39.02% |
| 2020 | 77.62% |
| 2019 | -16.74% |
| 2018 | -34.36% |
| 2017 | -12.46% |
| 2016 | 38.43% |
| 2015 | 2.49% |